BRAF MUTATIONS AND CO-OCCURRING ALTERATIONS
Genomic Alterations Associated with
BRAF
Alterations in Metastatic Breast Cancer
Alteration Type
Samples
Amplification 43 (51.8%)
V600E 13 (15.7%)
K601E
3 (3.6%)
Other Missense 18 (21.6%)
Fusions
5 (6%)
Uncharacterized
3 (3.6%)
BRAF
GA that lead to aberrant MAPK
signaling
Fusions Identified
Samples
KIAA1549-BRAF
2 (2.4%)
AGK-BRAF
1 (1.2%)
FCHSD2-BRAF
1 (1.2%)
KLHDC10-BRAF
1 (1.2%)
Co-occurring genomic alterations
Gene
Significance
*
Reduced Co-Occurrence
ERBB2
P = 0.011
Increased Co-Occurrence
MET
P < 0.01
HGF
P < 0.001
CDK6
P = 0.001
BRAF
fusions
B-RAF Mutations N=88 (1.1%)
Albanell et al. ESMO 2016
Foundation One panel study of > 6000 mBC Patients
